MA-4604

MA-4604 is an oral, small molecule drug in preclinical development by Maipl Therapeutics. It is a highly potent and selective antagonist of the Prostaglandin-F2α receptor (FP). The drug is designed as a non-hormonal therapy for endometriosis, aiming to reduce menstrual pain associated with dysregulated smooth muscle contractions and inflammation. Preclinical studies have shown that MA-4604 robustly reduces uterine contractions, lesion burden, and pain response in validated animal models. It has demonstrated high potency at sub-nanomolar concentrations, over 100-fold selectivity for the PGF2α pathway compared to other prostaglandin pathways, excellent pharmacokinetics suitable for oral administration, and a clean safety profile based on extensive in vitro assessments. The first-in-human Phase 1 study is expected to begin in Q2 2026. Additionally, it is being explored for idiopathic pulmonary fibrosis[1][2][3][4][6][7].